Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
5.
Hemoglobin ; 45(6): 371-379, 2021 Nov.
Article in English | MEDLINE | ID: covidwho-1240824

ABSTRACT

During the coronavirus-19 disease (COVID-19) pandemic, several studies were performed to determine the mortality and incidence rates of coronavirus infection among patients with hemoglobinopathies. However, there has been no systematic approach or meta-analysis to evaluate the results worldwide. This meta-analysis summarized the existing evidence of incidence and mortality rates of COVID-19 and related risk factors among patients with hemoglobinopathies with a focus on ß-thalassemia (ß-thal) and sickle cell disease. The review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist. Two authors independently screened the articles, extracted eligible ones, and assessed the quality of studies using the Joanna Briggs Institute (JBI) checklist. The collected data were analyzed by the Stata software. The amount of heterogeneity was demonstrated by the I2 test. The incidence of COVID-19 among patients with a hemoglobinopathy, ß-thal and sickle cell disease was 4.44, 1.34, and 17.22 per 100,000 person-day, respectively, to June 15 2020. The mortality rate of COVID-19 in patients with hemoglobin (Hb) disorders was calculated as 1.07 per 1000 person-day in the same period. Our findings showed a higher incidence rate of COVID-19 in sickle cell disease patients compared to the general population. A slightly higher mortality rate was also observed in patients with hemoglobinopathies compared to the general population, possibly due to the associated risk factors and comorbidities in this vulnerable group, which underscore special care, timely diagnosis and management along with current immunization, were crucial in decreasing the frequency, disease severity and mortality of these patients.


Subject(s)
Anemia, Sickle Cell , COVID-19 , Hemoglobinopathies , beta-Thalassemia , Anemia, Sickle Cell/complications , Anemia, Sickle Cell/epidemiology , COVID-19/epidemiology , Hemoglobinopathies/epidemiology , Humans , Incidence , beta-Thalassemia/epidemiology
6.
Transfus Clin Biol ; 28(1): 60-67, 2021 Feb.
Article in English | MEDLINE | ID: covidwho-1065637

ABSTRACT

OBJECTIVES: With the advent of COVID-19 in Pakistan, the already fragmented blood transfusion services (BTS) received a severe blow, putting the lives of transfusion-dependent thalassemia children on stake. This study aimed to assess the impact of the COVID-19 on blood transfusion therapy (BTT) of thalassemia patients and suggest ways to ensure safe and reliable blood supplies amid such health crises. MATERIAL AND METHODS: A retrospective, cross-sectional study was conducted from October 2019 (before COVID-19) to July 2020 (during COVID-19) based on the data provided by a thalassemia center, named Help International Welfare Trust, Karachi, Pakistan. SPSS version 24.0 was used for the data analysis. Data were described in the form of means and percentages. RESULTS: There was a significant reduction in the consumption of PRBCs bags after the emergence of COVID-19 (P=0.002). Moreover, the number of thalassemia patients receiving BTT was dropped by 10.56% during the pandemic. There was a strong negative correlation observed between the rising cases of COVID-19 in Pakistan and the number of patients missing their therapy sessions (r=-0.914, P=0.030). A considerable decline in the reserves of all Rhesus-negative blood groups amid the COVID-19 outbreak was also observed. CONCLUSION: The COVID-19 pandemic adversely affected the already suboptimal care catered to thalassemia patients in Karachi, Pakistan. The fear of the virus contraction coupled with the lockdown and restricted mobility has disrupted the entire transfusion chain from donor to the recipient. Collaborated efforts by the government and healthcare authorities are essential to ensure sufficient blood for thalassemia patients amid the pandemic.


Subject(s)
Blood Donors/supply & distribution , Blood Transfusion/statistics & numerical data , COVID-19 , Continuity of Patient Care , Pandemics , SARS-CoV-2 , beta-Thalassemia/therapy , Adolescent , Blood Grouping and Crossmatching , Child , Child, Preschool , Cross-Sectional Studies , Female , Health Services Accessibility , Humans , Male , Pakistan/epidemiology , Patient Acceptance of Health Care , Patient Compliance , Procedures and Techniques Utilization , Retrospective Studies , Rural Population , beta-Thalassemia/epidemiology
7.
Hemoglobin ; 45(1): 1-4, 2021 Jan.
Article in English | MEDLINE | ID: covidwho-1012736

ABSTRACT

ß-Thalassemia (ß-thal) is one of the most common inherited diseases all over the world. These patients are very susceptible to infection disease, and the mortality and morbidity of infected patients will increase. The object of this systematic review study was to determine mortality and morbidity of infected ß-thal patients with coronavirus disease 2019 (COVID-19). We searched PubMed, Elsevier, and Scholar Google to obtain related papers. The time of search was 21 June until 17 July 2020. All original and review articles and case reports were searched with key words: COVID 19, beta or ß-thalassemia (ß-thal), mortality and morbidity. Data were extracted after quality assessment of all articles. We obtained seven, 21 and six articles from PubMed, Scholar Google and Science Direct, respectively. Finally, seven articles were discussed in our study. The total number of enrolled patients was 34. Twenty-six patients carried transfusion-dependent ß-thal major (ß-TM). The most common symptoms were fever, cough, pain and dyspnea. Nine patients died. The result of this study has shown that the mortality and morbidity of infected ß-thal patients will escalate.


Subject(s)
COVID-19/epidemiology , Pandemics , SARS-CoV-2 , beta-Thalassemia/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Anticoagulants/therapeutic use , COVID-19/mortality , Comorbidity , Diabetes Mellitus/epidemiology , Female , Global Health , Hospitalization/statistics & numerical data , Humans , Hypertension, Pulmonary/epidemiology , Immunocompromised Host , Male , Middle Aged , Splenectomy/adverse effects , Thrombophilia/drug therapy , Thrombophilia/etiology , Young Adult , beta-Thalassemia/mortality , beta-Thalassemia/surgery
8.
Acta Biomed ; 91(3): e2020007, 2020 09 07.
Article in English | MEDLINE | ID: covidwho-761246

ABSTRACT

BACKGROUND: Coronavirus disease 2019 (COVID-19) outbreak is a global and challenging disease that is accompany with mortality and morbidity. AIM OF STUDY: We evaluated the prevalence and the impact of comorbidities in thalassemia Iranian patients affected by COVID-19.  Methods: A multicenter, retrospective, cross-sectional study was conducted across all comprehensive thalassemia centers in Iran, from January to June 15th, 2020. RESULTS: Forty-three confirmed COVID-19 thalassemia patients (32 TDT, and 11 NTDT) were detected. The mean age of patients was 35.3 ± 11.5 years (range 9 - 67); 21 females and 22 males. Overall, 78.1% of TDT and 90.9% of NTDT patients were complicated with at least one comorbidity (P: 0.656). The overall mortality rate of thalassemia patients with COVID-19 was 18.6% while 27.3% was in NTDT patients compared to 15.6% in TDT patients (P:0.401). The dead group had a non-significant higher frequency of endocrinopathies compared to the recovered group (62.5% versus 45.7% P:0.457). Ten female thalassemia patients with positive COVID-19 had hypogonadism, six patients were receiving hormone replacement therapy and all of them recovered (zero death) compared to two deaths from 4 patients who were not receiving hormone replacement therapy (P:0.133). Furthermore, the prevalence of COVID-19 in NTDT patients was significantly higher than the general population (45 per 10,000 versus 22.29 per 10,000 respectively, P:0.018) while the prevalence of TDT was almost similar to the normal population (P:0.539). The mortality rate of COVID-19 was 4.71% in the normal Iranian population compared to 18.6% in ß-thalassemias (P: <0.001) at the same date. CONCLUSIONS: It is important to acknowledge that ß-thalassemia patients, especially young adults/adults, have a chronic condition which may contribute to increase susceptibility to SARS-CoV-2 infection. A higher susceptibility to the infection was observed in patients with NTDT and in untreated hypogonadal female thalassemic patients. However, to confirm these data, more accurate designed studies are needed.


Subject(s)
Betacoronavirus , Blood Transfusion , Coronavirus Infections/epidemiology , Disease Transmission, Infectious/prevention & control , Pneumonia, Viral/epidemiology , Population Surveillance , beta-Thalassemia/epidemiology , Adolescent , Adult , Aged , COVID-19 , Child , Comorbidity , Coronavirus Infections/transmission , Cross-Sectional Studies , Female , Humans , Iran/epidemiology , Male , Middle Aged , Pandemics , Pneumonia, Viral/transmission , Prevalence , Prognosis , Retrospective Studies , SARS-CoV-2 , Survival Rate/trends , Young Adult , beta-Thalassemia/therapy
11.
Med Hypotheses ; 142: 109827, 2020 Sep.
Article in English | MEDLINE | ID: covidwho-352336

ABSTRACT

The novel coronavirus pneumonia (COVID-19) is a contagious acute respiratory infectious disease whose causative agent has been demonstrated to be a novel virus of the coronavirus family, SARSCoV-2. A recent PRE-print study has showed a heme attack on the 1-beta chain of hemoglobin by COVID19. Beta-thalassemia results of a default in the hemoglobin beta-chain synthesis. 1,5% global population are heterozygotes for this disease. In this study, by a multiple linear regression, we have analyzed the evolution of COVID-19 infection in three Italian regions (Puglia, Sardinia, Sicilia) with different beta-thalassemic prevalences, in order to search a link. The results have showed that betathalassemic heterozygote population prevalence is correlated to immunity against COVID-19, by a regression. This paper is only for academic discussion, the hypotheses and conclusions needs to be confirmed by further research.


Subject(s)
Coronavirus Infections/immunology , Pneumonia, Viral/immunology , beta-Thalassemia/immunology , Betacoronavirus , COVID-19 , Coronavirus Infections/complications , Female , Hemoglobins/analysis , Hemoglobins/chemistry , Heterozygote , Humans , Immune System , Immunization , Italy/epidemiology , Male , Middle Aged , Pandemics , Pneumonia, Viral/complications , Prevalence , Regression Analysis , SARS-CoV-2 , Treatment Outcome , beta-Thalassemia/complications , beta-Thalassemia/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL